Patients with relapsing-remitting multiple sclerosis (RRMS) in England, Wales and Northern Ireland can now access treatment with Biogen's oral therapy Vumerity, after NICE recommended the drug for ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of ...

Biogen's revenues declined 3% in the first nine months of 2024. Sales of Biogen’s key multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and spinal muscular atrophy (SMA) treatment ...

They also emphasized continued interest in neurology while acknowledging the strength of Biogen’s immunology capabilities from its multiple sclerosis franchise and the need to diversify further.

In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...

Ozanimod▼ is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active ...

2024 Biogen raised its annual profit forecast on Wednesday, as new treatments and cost-cutting measures offset declining sales of its multiple sclerosis drugs. Biogen lifts annual profit forecast ...

BTIG analyst Thomas Shrader has maintained their neutral stance on BIIB stock, giving a Hold rating on January 23.Invest with Confidence: ...